Structure Therapeutics (NASDAQ:GPCR) Trading Down 3.9%

Structure Therapeutics Inc. (NASDAQ:GPCR)’s share price was down 3.9% during trading on Tuesday . The stock traded as low as $38.20 and last traded at $38.43. Approximately 165,047 shares changed hands during trading, a decline of 79% from the average daily volume of 802,531 shares. The stock had previously closed at $40.00.

Analyst Ratings Changes

Several equities analysts have recently commented on GPCR shares. JMP Securities reiterated a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a research report on Friday, May 10th. JPMorgan Chase & Co. started coverage on Structure Therapeutics in a research report on Tuesday, May 21st. They set an “overweight” rating and a $65.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday. Finally, BMO Capital Markets raised their price target on Structure Therapeutics from $83.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, June 7th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics has an average rating of “Buy” and a consensus price target of $85.25.

Structure Therapeutics Stock Performance

The firm has a 50-day moving average of $41.59 and a 200-day moving average of $41.51. The firm has a market capitalization of $1.82 billion, a P/E ratio of -50.48 and a beta of -3.59.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.02. Equities analysts anticipate that Structure Therapeutics Inc. will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Sectoral Asset Management Inc. purchased a new position in shares of Structure Therapeutics in the 4th quarter valued at approximately $139,000. ADAR1 Capital Management LLC bought a new stake in shares of Structure Therapeutics in the 4th quarter worth $163,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Structure Therapeutics by 208.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,349 shares of the company’s stock worth $177,000 after purchasing an additional 2,939 shares in the last quarter. Raymond James & Associates bought a new stake in shares of Structure Therapeutics in the fourth quarter worth $233,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Structure Therapeutics in the fourth quarter worth $277,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.